While HOXA10 was recently shown to drive the expression of genes with critical roles in gliomagenesis [14] and to increase temozolomide resistance in vitro [15], the downstream mechanisms by which HOXA9 may contribute to poor outcomes in GBM patients have not been addressed. This evidence concerns the gene HOXA10 and glioblastoma.